<DOC>
	<DOCNO>NCT02191813</DOCNO>
	<brief_summary>Study detect efficacy SeresisÂ® reduce damage produce skin Matrix-metalloproteinases ( MMP ) oxidative stress ( marker : heme oxygenase-1 expression ) activate UV radiation</brief_summary>
	<brief_title>Study Determine Ability Seresis Act Skin Protection Agent Healthy Young Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy female volunteer 18 30 year With skin type I skin type II Body Mass Index &gt; 25 Nonsmokers Volunteers give write informed consent accord Good Clinical Practice ( GCP ) local regulation Any serious disorder may interfere participation trial evaluation safety test drug ( e.g . liver and/or renal disease , hypervitaminosis A , psychic disorder , etc . ) , and/or treatment chronic medication Pretreatment ( less 2 week prior inclusion trial ) and/or concomitant treatment drug may influence trial symptomatology may interfere evaluation safety test drug ( e.g . vitamin mineral supplementation ) Relevant allergy know hypersensitivity investigational drug excipients High performance sport people Alcohol drug abuse accord Diagnostic Statistics Manual ( DSMIV ) Female volunteer childbearing age use adequate mean birth control ( contraceptive pill , intrauterine device ( IUDs ) , sterilization ) Pregnancy and/or lactation Known abnormal value lab test ( detected enrolment , subject continue treatment provide medical objection ) Abnormal value Aspartate Transferase ( SGOT/ASAT ) , Alanine Transferase ( SGPT/ALAT ) , Gammaglutamyl transpeptidase , Low density Lipoproteins/Triglycerides ( LDL/TGL ) level blood Participation another clinical trial within last 4 week concurrent participation another clinical trial Specific dietary requirement allow volunteer meet dietary guideline set study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>